Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Sandra H. Clark"'
Publikováno v:
Journal of Cutaneous Pathology. 39:787-790
We report the case of a 62-year-old white male who presented with a 2.6-cm ulcerating mass on the skin of the left buttock and ipsilateral inguinal lymphadenopathy. Microscopic sections of the skin lesion showed a nodular and plaque-like growth patte
Publikováno v:
Cancer Research. 78:4901-4901
Introduction: Neuroblastoma is the most common extracranial solid tumor in childhood and accounts for ~15% of all pediatric cancer mortality. Approximately 650 new cases are reported annually in the USA, with 90% of cases diagnosed by 5 years of age.
Autor:
Xin Zheng, Abdelhadi Rebbaa, Bernard L. Mirkin, Marianne E. Greene, Bryan D. White, Fei Chu, Sandra H. Clark
Publikováno v:
Oncogene. 24:4965-4974
Resistance to cytotoxic agents is a major limitation for their clinical use to treat human cancers. Tumors become resistant to chemotherapy when a subset of cells undergoes molecular changes leading to overexpression of drug transport proteins, alter
Autor:
Sandra H. Clark, Victor G. Prieto
Publikováno v:
Annals of Diagnostic Pathology. 6:257-264
Within the last years, evaluation of sentinel lymph nodes (SLN) has become the most popular method of early staging of several malignancies, including breast carcinoma and melanoma. Because SLN are reportedly the lymph nodes most likely to contain me
Publikováno v:
Journal of Cutaneous Pathology. 30:279-281
Background: Gleevec™ is a protein tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumor. Currently, Gleevec is also being used in protocols for treatment of other malignancies such as mel
A new type of polymer nanoparticle (PNP) containing a high density of covalently linked doxorubicin, attached via a non-cleavable amine linkage (amine-linked Dox-PNP) was prepared. Together with a previously reported cleavable carbamate-linked Dox-PN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::749bcc3b79941ee7078234772f2ee1b8
https://europepmc.org/articles/PMC3888582/
https://europepmc.org/articles/PMC3888582/
Publikováno v:
Archives of pathologylaboratory medicine. 128(10)
Publikováno v:
Journal of cutaneous pathology. 30(4)
Gleevec trade mark is a protein tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumor. Currently, Gleevec is also being used in protocols for treatment of other malignancies such as melanom
Autor:
Timothy B. Lautz, Chunfa Jie, Y. Qiu, X. Zheng, Mary Beth Madonna, Fei Chu, Sandra H. Clark, Nadereh Jafari, Jessica A. Naiditch, M. Czurylo
Publikováno v:
Cell Death & Disease
Numerous studies have confirmed that cancer stem cells (CSCs) are more resistant to chemotherapy; however, there is a paucity of data exploring the effect of long-term drug treatment on the CSC sub-population. The purpose of this study was to investi
Publikováno v:
Archives of Pathology & Laboratory Medicine. 128:e129-e130